The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Vol.
33
No.
19
May 18, 2007May 18, 2007
Free
DOWNLOAD THE PDF

After ODAC: Questions On ESA Claims, Advertising, Reimbursement Gain Urgency.

Amgen Claimed QOL Benefit Despite FDA Label Change.

“Miracle-Gro for Cancer?” ODAC Members Vent At Amgen And J&J Over Claims, Advertising.

FDA Begins To Examine Its Role In Allowing Misleading Consumer Advertising.

CMS Proposal To Limit ESA Use Is Too Much, Too Fast, Critics Say.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account